XML 52 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1
Impairment Testing
12 Months Ended
Dec. 31, 2018
Notes to Consolidated Financial Statements [Abstract]  
Note 13 - Impairment Testing

Note 13 - Impairment Testing

 

Impairment testing for intangible assets with an indefinite useful life

 

Goodwill - The goodwill is not monitored for internal reporting purposes and, accordingly, it is allocated to the Company’s operating segments and not to the cash-generating units, the level of which is lower than the operating segment. The examination of impairment in the carrying amount of the goodwill is made accordingly.

Trademarks - For impairment testing purpose, the trademarks with indefinite useful life were allocated to the cash-generating units, which represent the lowest level within the Company.

 

The carrying amounts of intangible assets with an indefinite useful life are as follows:

 

As at December 31

 

2018

2017

 

$ millions

$ millions

 

Goodwill

 

 

Phosphate Solutions

127

140

Industrial Products

92

93

Innovative Ag. Solutions

71

73

Potash

19

20

 

309

326

 

 

 

Trademarks

 

 

Industrial Products, United States

13

13

Phosphate Solutions, United States

12

12

Industrial Products, Europe

5

6

 

30

31

 

339

357

 


Note 13 - Impairment Testing (cont’d)

 

Impairment testing for intangible assets with an indefinite useful life (cont’d)

As a result of a structural change, which entered into effect on August 31, 2018, (see Note 5) the Company is operating through four business segments and consequently, goodwill has been reallocated to the new segments. The comparative Goodwill amounts have been restated to reflect this change.

In preparation of the goodwill impairment testing, the aftertax discount rate used for the calculation of the recoverable amount of the operating segments is 9.5% nominal. The longterm growth rate is between 0% and 2%, in industries and markets in which the Company is engaged.

The recoverable amount of the operating segments was determined based on their value in use, which is an internal valuation of the discounted future cash flows that will be generated from the continuing operation of the operating segments. The examinations determined that the carrying amount of the operating segments is lower than their recoverable amount and, accordingly, no impairment loss was recognized.